CD10 as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma

T. Fukusumi, H. Ishii, M. Konno, T. Yasui, S. Nakahara, Y. Takenaka, Y. Yamamoto, S. Nishikawa, Y. Kano, H. Ogawa, S. Hasegawa, A. Hamabe, N. Haraguchi, Y. Doki, Masaki Mori, H. Inohara

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background: Cancer stem cells (CSCs) are responsible for treatment failure. However, their identification and roles in resistance are not well established in head and neck squamous cell carcinoma (HNSCC).Methods:Three HNSCC cell lines (FaDu, Detroit562 and BICR6) were treated with cisplatin or radiation. Cell surface antigens were analysed by LyoPlate, a novel cell surface antigen array. The expression levels of antigens highly expressed after treatments were further compared between cisplatin-resistant Detroit562 cells and its parental line. Association of the candidate antigen with CSCs properties, namely sphere formation and in vivo tumourigenicity, was also examined.Results:CD10, CD15s, CD146 and CD282 were upregulated across the treated cell lines, while the increased expression of CD10 was prominent in the cisplatin-resistant cell line. Isolation mediated by FACS revealed that the CD10-positive subpopulation was more refractory to cisplatin, fluorouracil and radiation than the CD10-negative subpopulation. It also showed an increased ability to form spheres in vitro and tumours in vivo. Moreover, the CD10-positive subpopulation expressed the CSC marker OCT3/4 at a higher level than that in the CD10-negative subpopulation.Conclusions:CD10 is associated with therapeutic resistance and CSC-like properties of HNSCC. CD10 may serve as a target molecule in the treatment of refractory HNSCC.

Original languageEnglish
Pages (from-to)506-514
Number of pages9
JournalBritish journal of cancer
Volume111
Issue number3
DOIs
Publication statusPublished - Jul 29 2014
Externally publishedYes

Fingerprint

Neoplastic Stem Cells
Cisplatin
Surface Antigens
Cell Line
Radiation
Antigens
Therapeutics
Treatment Failure
Fluorouracil
Carcinoma, squamous cell of head and neck
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Fukusumi, T., Ishii, H., Konno, M., Yasui, T., Nakahara, S., Takenaka, Y., ... Inohara, H. (2014). CD10 as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma. British journal of cancer, 111(3), 506-514. https://doi.org/10.1038/bjc.2014.289

CD10 as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma. / Fukusumi, T.; Ishii, H.; Konno, M.; Yasui, T.; Nakahara, S.; Takenaka, Y.; Yamamoto, Y.; Nishikawa, S.; Kano, Y.; Ogawa, H.; Hasegawa, S.; Hamabe, A.; Haraguchi, N.; Doki, Y.; Mori, Masaki; Inohara, H.

In: British journal of cancer, Vol. 111, No. 3, 29.07.2014, p. 506-514.

Research output: Contribution to journalArticle

Fukusumi, T, Ishii, H, Konno, M, Yasui, T, Nakahara, S, Takenaka, Y, Yamamoto, Y, Nishikawa, S, Kano, Y, Ogawa, H, Hasegawa, S, Hamabe, A, Haraguchi, N, Doki, Y, Mori, M & Inohara, H 2014, 'CD10 as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma', British journal of cancer, vol. 111, no. 3, pp. 506-514. https://doi.org/10.1038/bjc.2014.289
Fukusumi, T. ; Ishii, H. ; Konno, M. ; Yasui, T. ; Nakahara, S. ; Takenaka, Y. ; Yamamoto, Y. ; Nishikawa, S. ; Kano, Y. ; Ogawa, H. ; Hasegawa, S. ; Hamabe, A. ; Haraguchi, N. ; Doki, Y. ; Mori, Masaki ; Inohara, H. / CD10 as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma. In: British journal of cancer. 2014 ; Vol. 111, No. 3. pp. 506-514.
@article{7471b8e3ee5a491687e31ae7211855e7,
title = "CD10 as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma",
abstract = "Background: Cancer stem cells (CSCs) are responsible for treatment failure. However, their identification and roles in resistance are not well established in head and neck squamous cell carcinoma (HNSCC).Methods:Three HNSCC cell lines (FaDu, Detroit562 and BICR6) were treated with cisplatin or radiation. Cell surface antigens were analysed by LyoPlate, a novel cell surface antigen array. The expression levels of antigens highly expressed after treatments were further compared between cisplatin-resistant Detroit562 cells and its parental line. Association of the candidate antigen with CSCs properties, namely sphere formation and in vivo tumourigenicity, was also examined.Results:CD10, CD15s, CD146 and CD282 were upregulated across the treated cell lines, while the increased expression of CD10 was prominent in the cisplatin-resistant cell line. Isolation mediated by FACS revealed that the CD10-positive subpopulation was more refractory to cisplatin, fluorouracil and radiation than the CD10-negative subpopulation. It also showed an increased ability to form spheres in vitro and tumours in vivo. Moreover, the CD10-positive subpopulation expressed the CSC marker OCT3/4 at a higher level than that in the CD10-negative subpopulation.Conclusions:CD10 is associated with therapeutic resistance and CSC-like properties of HNSCC. CD10 may serve as a target molecule in the treatment of refractory HNSCC.",
author = "T. Fukusumi and H. Ishii and M. Konno and T. Yasui and S. Nakahara and Y. Takenaka and Y. Yamamoto and S. Nishikawa and Y. Kano and H. Ogawa and S. Hasegawa and A. Hamabe and N. Haraguchi and Y. Doki and Masaki Mori and H. Inohara",
year = "2014",
month = "7",
day = "29",
doi = "10.1038/bjc.2014.289",
language = "English",
volume = "111",
pages = "506--514",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - CD10 as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma

AU - Fukusumi, T.

AU - Ishii, H.

AU - Konno, M.

AU - Yasui, T.

AU - Nakahara, S.

AU - Takenaka, Y.

AU - Yamamoto, Y.

AU - Nishikawa, S.

AU - Kano, Y.

AU - Ogawa, H.

AU - Hasegawa, S.

AU - Hamabe, A.

AU - Haraguchi, N.

AU - Doki, Y.

AU - Mori, Masaki

AU - Inohara, H.

PY - 2014/7/29

Y1 - 2014/7/29

N2 - Background: Cancer stem cells (CSCs) are responsible for treatment failure. However, their identification and roles in resistance are not well established in head and neck squamous cell carcinoma (HNSCC).Methods:Three HNSCC cell lines (FaDu, Detroit562 and BICR6) were treated with cisplatin or radiation. Cell surface antigens were analysed by LyoPlate, a novel cell surface antigen array. The expression levels of antigens highly expressed after treatments were further compared between cisplatin-resistant Detroit562 cells and its parental line. Association of the candidate antigen with CSCs properties, namely sphere formation and in vivo tumourigenicity, was also examined.Results:CD10, CD15s, CD146 and CD282 were upregulated across the treated cell lines, while the increased expression of CD10 was prominent in the cisplatin-resistant cell line. Isolation mediated by FACS revealed that the CD10-positive subpopulation was more refractory to cisplatin, fluorouracil and radiation than the CD10-negative subpopulation. It also showed an increased ability to form spheres in vitro and tumours in vivo. Moreover, the CD10-positive subpopulation expressed the CSC marker OCT3/4 at a higher level than that in the CD10-negative subpopulation.Conclusions:CD10 is associated with therapeutic resistance and CSC-like properties of HNSCC. CD10 may serve as a target molecule in the treatment of refractory HNSCC.

AB - Background: Cancer stem cells (CSCs) are responsible for treatment failure. However, their identification and roles in resistance are not well established in head and neck squamous cell carcinoma (HNSCC).Methods:Three HNSCC cell lines (FaDu, Detroit562 and BICR6) were treated with cisplatin or radiation. Cell surface antigens were analysed by LyoPlate, a novel cell surface antigen array. The expression levels of antigens highly expressed after treatments were further compared between cisplatin-resistant Detroit562 cells and its parental line. Association of the candidate antigen with CSCs properties, namely sphere formation and in vivo tumourigenicity, was also examined.Results:CD10, CD15s, CD146 and CD282 were upregulated across the treated cell lines, while the increased expression of CD10 was prominent in the cisplatin-resistant cell line. Isolation mediated by FACS revealed that the CD10-positive subpopulation was more refractory to cisplatin, fluorouracil and radiation than the CD10-negative subpopulation. It also showed an increased ability to form spheres in vitro and tumours in vivo. Moreover, the CD10-positive subpopulation expressed the CSC marker OCT3/4 at a higher level than that in the CD10-negative subpopulation.Conclusions:CD10 is associated with therapeutic resistance and CSC-like properties of HNSCC. CD10 may serve as a target molecule in the treatment of refractory HNSCC.

UR - http://www.scopus.com/inward/record.url?scp=84905277260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905277260&partnerID=8YFLogxK

U2 - 10.1038/bjc.2014.289

DO - 10.1038/bjc.2014.289

M3 - Article

C2 - 24874475

AN - SCOPUS:84905277260

VL - 111

SP - 506

EP - 514

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 3

ER -